KRYS (Krystal Biotech, Inc.) חוב לטווח קצר להון

The visualized price action for Krystal Biotech, Inc. (KRYS) reflects the dynamics of a business growing independently of macroeconomic trends due to its unique gene therapy. The indicator stands at 0.00. Krystal Biotech, Inc. (KRYS) relies on external contractors (CRO/CMO) for testing and drug production; however, risks persist regarding the reliance on a single product, the complexity of biomaterial delivery, and disputes with insurers over treatment pricing.

Krystal Biotech, Inc. (KRYS) maintains a monopoly position within the skin pathology gene therapy niche, ensuring exceptional pricing power and a steady flow of liquidity. The ratio of short-term liabilities to equity measures the business's reliance on urgent borrowing, allowing for an assessment of the issuer's financial stability via the current short-term debt-to-equity ratio during periods of market volatility.